ID   K562-Wnt5a
AC   CVCL_XE50
DR   CCRID; 4201PAT-CCTCC00313
DR   Wikidata; Q94335728
RX   Patent=CN101724603A;
RX   PubMed=21069266;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200958.
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 12784; WNT5A.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 29-06-23; Version: 10
//
RX   Patent=CN101724603A;
RA   Si W.-K., Li J., Li Z.-Q., Pan J., Niu C.-C., Zhao W.;
RT   "Transgenic cell K562-Wnt5a and preparation method thereof.";
RL   Patent number CN101724603A, 09-Jun-2010.
//
RX   PubMed=21069266; DOI=10.3892/ijmm.2010.560;
RA   Yuan Y., Niu C.-C., Deng G., Li Z.-Q., Pan J., Zhao C., Yang Z.-L.,
RA   Si W.-K.;
RT   "The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt
RT   signaling in K562 cells.";
RL   Int. J. Mol. Med. 27:63-69(2011).
//